Business
Director/PDMR Shareholding
Director/PDMR Shareholding.
About this update from Renalytix Plc
[{"type":"text","content":"\n \n \n Renalytix plc \n \n \n (\"Renalytix\" or the \"Company\")\n \n \n \n \n \n Director/PDMR Dealing\n \n \n \n \n \n \n \n \n LONDON and SALT LAKE CITY, February 10, 2023\n \n -- \n \n \n Renalytix plc\n \n \n \n (NASDAQ: RNLX) (LSE: RENX) confirms that further to the announcement on February 8 of a c.$20.3 million private placement, the Company has been informed that certain investment vehicles connected with Christopher Mills, Non-Executive Chairman, have completed the purchase of 346,375 ordinary shares of £0.0025 each (\"Ordinary Shares\") in the Company at a price of £0.90 per Ordinary Share.\n \n \n \n \n \n Following completion of this purchase, Christopher Mills and the investment vehicles connected with him are interested in 10,072,500 Ordinary Shares representing 10.8% of the issued share capital of the Company as enlarged by the recent private placement.\n \n \n \n \n \n For further information, please contact:\n \n \n \n \n \n \n \n \n \n \n Renalytix plc \n \n \n \n \n \n \n www.renalytix.com\n \n \n \n \n \n \n \n \n James McCullough, CEO \n \n \n \n \n \n Via Walbrook PR \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n Stifel (Nominated Adviser, Joint Broker)\n \n \n \n \n \n Tel: 020 7710 7600\n \n \n \n \n \n \n \n Alex Price / Nicholas Moore \n / Nick Harland / Samira Essebiyea\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n Walbrook PR Limited\n \n \n \n \n \n Tel: 020 7933 8780 \n or \n \n [email protected]\n \n \n \n \n \n \n \n \n Paul McManus / Lianne Applegarth\n \n \n \n \n Mob: 07980 541 893 / 07584 391 303\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n About Kidney Disease\n \n \n \n Kidney disease is a public health epidemic affecting over 850 million people globally.1 The Centers for Disease Control and Prevention estimates that 15% of U.S. adults, or approximately 37 million people2, have chronic kidney disease (CKD). Nearly 95% of people with CKD are in early stages 1-33. Despite its magnitude, early-stage (1-3) CKD is underdiagnosed and undertreated, largely because it's asymptomatic at this time in the disease. As many as 9 in 10 adults with CKD, and about 2 in 5 ...